Navigation Links
Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
Date:12/7/2010

ribed affirmatively in regulatory guidance documents.  We believe we achieve the same benefits with centralized psychiatric assessments," he said.

The Cipher study has required MedAvante centralized raters to conduct over 8,100 remote, live assessments of patients at 50 sites in the U.S. and Canada, and to report timely results to the sites.  "MedAvante's role in the Cipher study demonstrates our ability to seamlessly integrate centralized raters into most non-psychiatric studies, by providing responsive operational logistics and without interfering in standard study procedures – earning the acceptance of the dermatologists in the study," said Gilbert.

MedAvante's centralized raters are mental health professionals with deep clinical and rating scale expertise, carefully selected through an intensive qualification process, and continuously trained and calibrated.  

About MedAvante, Inc.

MedAvante is the premier global provider of centralized expert psychiatric rating and monitoring services to the pharmaceutical, biotechnology and medical device industries. Its flagship service, Remote Centralized Ratings, provides real-time assessments, either by telephone or videoconference, of subjects in global drug trials. Centralizing the assessors and blinding them to study protocols results in a level of standardization, calibration and objectivity that is not achievable with a decentralized group of study raters participating from unconnected investigative sites. In addition to Centralized Ratings, the company provides Continuous Quality Control (CQC), a monitoring service in which expert calibrated trainers review site-based study interviews via audio and video.  MedAvante solutions help sponsors achieve increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. MedAvante operates facilities in Hamilton, NJ; Madison, WI; and Moscow, Russia.  For more informat
'/>"/>

SOURCE MedAvante, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
2. Medicomps Decipher Holter Monitor Provides Cardiac Reporting on the International Space Station
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... their offering. The Central Nervous System (CNS) ... of pharmaceuticals industry. The numbers of CNS disorders have increased ... to meet the market requirements. There has been steady to ... the past two decades. The market for CNS therapies is ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Barbara,Ann Karmanos Cancer Institute's Philip A. Philip, M.D., ... outcome,of one of the largest randomized phase III ... an education session about the,future of pancreatic cancer ... annual meeting in Chicago, IL. , The clinical ...
... - Data from first Phase 3 trial presented at ... 3 trial open the door for,patient recruitment in Europe ... 2007 --,Theratechnologies (TSX: TH) reported today that 26-week data ... were presented today in Toronto at ENDO, the 89th,annual ...
Cached Medicine Technology:Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 2Clinical Trial Results Change Standard of Care for Pancreatic,Cancer Patients, Future Therapies Discussed 3Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Grand Rapids, MI (PRWEB) August 30, 2014 ... Michigan residents, Forefront Dermatology is expanding with the addition ... Mich. Dr. David Hammond who has provided leading-edge skin ... practice with Forefront Dermatology. , “As a doctor, ... care they deserve. Through partnering with Forefront Dermatology, I’m ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:8/30/2014)... 30, 2014 "My wife suffered neck, ... car accident," said one of two inventors from Bethel, ... her shoulder and neck area. She tried other pillows ... and pressure, assisting in comfort and providing extra sleep." ... CRADLE to support the head, neck and back comfortably. ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... regimen in most cancer treatments. Since it is a very ... with something more comfortable for the patient. ,Now ... off the ovary and stop the production of a female ... agonist achieves a normal action, often mimicking the action of ...
... that intake of cruciferous vegetables with a high ... against bladder cancer. ... such as broccoli, cauliflower, kale, turnips, collards, Brussels ... ,They apply their anti-oxidant effect through down regulation ...
... only affects to work, sleep and performance of other activities ... memory and your concentration. ,This is the ... Saifudin Rashiq at the University of Alberta. ,As ... Multidisciplinary Pain Centre in Edmonton, Canada, the researchers studied 24 ...
... Researchers based at the National Cancer Institute and ... an antioxidant predominately found in tomatoes , does ... fact, the researchers noted an association between beta-carotene, ... risk for aggressive prostate cancer. ,It ...
... of a type of kidney malignancy called renal cancer according ... and Women's Hospital in Boston found that women and men ... were about 30 percent less likely to develop renal cell ... who drank beer, wine or liquor. ,Jung Eun ...
... the Australian National Audit Office found that the Department ... 100,000 people with tuberculosis to enter Australia but frequently ... treatment, The Australian reports. ,People with inactive ... sometimes are permitted to enter Australia if they sign ...
Cached Medicine News:Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Risk of Bladder Cancer Reduced by Broccoli and Cauliflower 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:Tomatoes are Not So Effective in Preventing Prostate Cancer 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: